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Background
Interleukin-6 type cytokines are mainly involved in
inflammation by controlling differentiation, proliferation,
migration, and apoptosis of target cells. A dysfunction of
the complex regulatory cytokine network might lead to
acute and chronic inflammation, autoimmune diseases or
neoplastic disorders. IL-6 deficient mice were found to
be resistant to collagen- and antigen-induced arthritis,
highlighting the role of IL-6 in chronic inflammation and
autoimmune diseases. The IL-6 receptor complex con-
sists of the signal-transducing gp130 receptor and the
non-signaling IL-6 receptor (IL-6R) which exists in mem-
brane bound and soluble forms. A soluble form of the
human IL-6R (sIL-6R) is mainly generated by limited
proteolysis (ectodomain shedding) but also by alternative
splicing. IL-6 signaling via the membrane-bound IL-6R
and gp130 is called classic signaling, whereas IL-6 signal-
ing via the soluble IL-6R and gp130 is referred to as IL-6
trans-signaling. Gp130 is ubiquitously expressed, whereas
the membrane-bound IL-6R is mainly expressed on lym-
phocytes and hepatocytes. Therefore, IL-6 trans-signaling
virtually expands IL-6 signaling to all cells of the body.
Using the specific trans-signaling inhibitor soluble gp130
(sgp130), we showed that IL-6R ectodomain shedding
which facilitates IL-6 trans-signaling is the crucial step in
the development and the progression of chronic inflam-
matory disorders and inflammation-induced cancer.
Structural requirements of IL-6R ectodomain
shedding
Most post-transcriptional modifications such as phos-
phorylation, which control the fate and activity of pro-
teins, are completely reversible. Proteolysis is exceptional
because of its irreversible nature. The proteolytic release
of membrane-anchored proteins was also called (ectodo-
main) shedding, and the responsible proteases were
termed “sheddases” [1].
Ectodomain shedding of the IL-6R has two functional
consequences. First, loss of membrane-bound IL-6R ren-
ders the cell non-responsive towards IL-6 classic signaling,
thereby abrogating IL-6 signaling. Paradoxically, the gener-
ated soluble IL-6R (sIL-6R) itself is biologically active and
can mediate IL-6 trans-signaling on cells expressing
gp130. A high concentration of 25–50 ng/ml sIL-6R is
found in the serum of healthy humans. Under pathophy-
siological conditions, sIL-6R levels rise up to three fold.
The cellular source of the sIL-6R and the in vivo mechan-
ism of its generation are still unclear. The vast majority
(90–99%) of the sIL-6R should originate from ectodomain
shedding of the membrane-bound precursor, whereas
alternative splicing of the IL-6R mRNA is accounts only
for a minor proportion (1–10%) [1].
The sIL-6R is generated by constitutive and induced
shedding by the “A disintegrin and metalloproteinases”
(ADAM)10 and ADAM17 [1]. Recently, we characterized
the structural requirements of IL-6R shedding on the site
of the substrate [2]. The IL-6R consists of three extracellu-
lar domains, important for efficient exocytosis and IL-6
binding. The extracellular domains are followed by a flex-
ible, 52 amino acids long stalk region, a trans-membrane
domain and an intracellular domain which regulate baso-
lateral sorting of the IL-6R [3]. The ADAM17 cleavage site
was identified within the stalk region between the amino
acids 357Q and 358D [1]. Deletion of 10 amino acids sur-
rounding the ADAM17 cleavage site abrogated ADAM17
shedding of the IL-6R but leaves ADAM10 shedding intact.
This suggested that the ADAM10 cleavage site is located at
a different site. Interestingly, ADAM proteases do not have
defined cleavage consensus sequences, which hinder the
identification of novel cleavage sites by substrate sequence
analysis. Deletion of 5 additional juxtamembrane located
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amino acids in the aforementioned delta10 IL-6R variant
abolishes also ADAM10-mediated ectodomain shedding of
the IL-6R [2], suggesting that the ADAM10 cleavage site is
in close proximity to the ADAM17 cleavage site. Impor-
tantly, both IL-6R variants (delta10 and delta15) are biolo-
gically active. Moreover, we showed that only about 20 of
the 52 amino acids of the IL-6R stalk region are needed for
biological activity of the IL-6R, which supported a model
of the IL-6/IL-6R/gp130 signal transducing complex, in
which the gp130 receptor chain has a C-shaped structure
after IL-6/IL-6R/gp130 complex formation [2]. In this
model, the stalk region is necessary for the correct posi-
tioning of the IL-6-binding domains of the IL-6R in the sig-
nal transducing receptor complex.
Constitutive shedding is dependent on the level
of cellular IL-6R expression
Apart from induced IL-6R shedding, which is activated by
various substances and conditions, including phorbol
esters such as phorbol-12-myristat-13-acetate (PMA), the
Ca2+ ionophor ionomycin, extracellular ATP, low mem-
brane-cholesterol levels and apoptosis [1], the IL-6R is
also constitutively released from the cell surface, without
obvious cellular stimulation. Here, we demonstrated that
cellular senescence and EGF-R stimulation lead to
increased IL-6R expression, which was regulated via the
mTOR pathway [4]. The simple increase in cell surface
expressed IL-6R also led to increased generation of sIL-6R,
suggesting that the expression level of the cellular sub-
strate indirectly determines the amount of constitutive
shedding. sIL-6R serum levels are increased under various
inflammatory conditions and up to now, it is not clear if
this is dependent on increased IL-6R expression, induced
or constitutive shedding. Or data, however, open up the
possibility that both mechanisms contribute to inflamma-
tion-induced increased sIL-6R levels.
Conclusions
In recent years, we characterized the biological functions of
IL-6 trans-signaling and sgp130, which specifically sup-
presses overshooting IL-6 trans-signaling activities but to
leaves “beneficial” IL-6 classic signaling intact. The biologi-
cal sgp130Fc is currently tested in phase I clinical trials [5].
In contrast to treatment with neutralizing TNFalpha anti-
bodies, administration of the trans-signaling inhibitor
sgp130 did not interfere with protective immune responses
after infection with Mycobacterium tuberculosis in mice
[3]. Moreover, classical signaling was sufficient for early
control of Listeria monocytogenes infection in mice [6].
Blockade of IL-6 trans-signaling might therefore exhibit
advantages as compared to the global blockade of IL-6 or
TNFalpha by monoclonal antibodies for the treatment of
chronic inflammatory diseases.
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